http://www.clinicaltrials.gov/ct/show/NCT00478465?order=4

Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients who have elevated antibody titers against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)

http://www.rocheusa.com/products/valcyte/

http://www.druglib.com/abstract/le/lerner-am_in-vivo_20070900.html

Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up.

Valtrex is an antiviral drug approved to treat genital herpes infection, herpes zoster (shingles) and herpes labialis (cold sores) infections. Dr. Martin Lerner of Royal Beaumont Hospital in Royal Oak, Michigan, is currently investigating its efficacy in chronic fatigue syndrome (ME/CFS) patients with Epstein-Barr virus infections. Valtrex is converted in the body to acyclovir which inhibits viral DNA replication. It is produced by GlaxoSmithKline

http://tinyurl.com/d5vuhj

http://med.stanford.edu/news_releases/2007/
january/montoya.html

José Montoya, MD, associate professor of medicine (infectious diseases), and postdoctoral scholar Andreas Kogelnik, MD, PhD, have used the drug valganciclovir — an antiviral often used in treating diseases caused by human herpes viruses — to treat a small number of CFS patients.